DE60238032D1 - Vorhersagen der wundheilung durch harnnitrat-bestimmung - Google Patents

Vorhersagen der wundheilung durch harnnitrat-bestimmung

Info

Publication number
DE60238032D1
DE60238032D1 DE60238032T DE60238032T DE60238032D1 DE 60238032 D1 DE60238032 D1 DE 60238032D1 DE 60238032 T DE60238032 T DE 60238032T DE 60238032 T DE60238032 T DE 60238032T DE 60238032 D1 DE60238032 D1 DE 60238032D1
Authority
DE
Germany
Prior art keywords
wound healing
patients
diabetic
impaired
nitric oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60238032T
Other languages
English (en)
Inventor
Joseph V Boykin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BOYKIN JUN
Original Assignee
BOYKIN JUN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BOYKIN JUN filed Critical BOYKIN JUN
Application granted granted Critical
Publication of DE60238032D1 publication Critical patent/DE60238032D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/795—Porphyrin- or corrin-ring-containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60238032T 2001-02-06 2002-02-05 Vorhersagen der wundheilung durch harnnitrat-bestimmung Expired - Lifetime DE60238032D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/776,926 US6436366B2 (en) 1999-03-19 2001-02-06 Prediction of wound healing by urinary nitrate assay
PCT/US2002/003204 WO2002063308A2 (en) 2001-02-06 2002-02-05 Prediction of wound healing by urinary nitrate assay

Publications (1)

Publication Number Publication Date
DE60238032D1 true DE60238032D1 (de) 2010-12-02

Family

ID=25108752

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60238032T Expired - Lifetime DE60238032D1 (de) 2001-02-06 2002-02-05 Vorhersagen der wundheilung durch harnnitrat-bestimmung

Country Status (10)

Country Link
US (1) US6436366B2 (de)
EP (1) EP1360508B1 (de)
JP (1) JP2004532389A (de)
AT (1) ATE485523T1 (de)
AU (1) AU2002245379B2 (de)
CA (1) CA2436465A1 (de)
DE (1) DE60238032D1 (de)
ES (1) ES2354868T3 (de)
MX (1) MXPA03007018A (de)
WO (1) WO2002063308A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030134332A1 (en) * 2001-11-28 2003-07-17 Boykin Joseph V. Diagnosis of endothelial dysfunction by nitric oxide bioactivity index
WO2004046155A2 (en) * 2002-11-20 2004-06-03 Boykin Jr Joseph V Predicting outcome of hyperbaric oxygen therapy treatment with nitric oxide bioavailability
US8303995B1 (en) 2008-06-13 2012-11-06 Board Of Regents, The University Of Texas System Nitrite formulations and their use as nitric oxide prodrugs
WO2013023217A1 (en) * 2011-08-11 2013-02-14 Board Of Regents, The University Of Texas System Method of measuring and monitoring in vivo nitrite levels
BR112014003414B1 (pt) 2011-08-17 2021-09-21 Board Of Regents, The University Of Texas System Composição e sistema de entrega oral para aumento de níveis fisiológicos e terapêuticos de óxido nítrico
WO2015034968A1 (en) * 2013-09-04 2015-03-12 Microbaric Oxygen Systems, Llc Hyperoxic therapy with oxygen dose-response model
US9492374B2 (en) 2015-03-25 2016-11-15 Jose Rafael Salinas Andrade Composition and method for treatment of ulcers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312663B1 (en) * 1999-03-19 2001-11-06 Joseph V. Boykin, Jr. Prediction of diabetes impaired wound healing by urinary nitrate assay

Also Published As

Publication number Publication date
AU2002245379B2 (en) 2007-09-06
EP1360508B1 (de) 2010-10-20
WO2002063308A3 (en) 2002-11-21
US6436366B2 (en) 2002-08-20
JP2004532389A (ja) 2004-10-21
US20010047035A1 (en) 2001-11-29
WO2002063308A2 (en) 2002-08-15
EP1360508A2 (de) 2003-11-12
MXPA03007018A (es) 2004-10-15
ATE485523T1 (de) 2010-11-15
CA2436465A1 (en) 2002-08-15
ES2354868T3 (es) 2011-03-18

Similar Documents

Publication Publication Date Title
MXPA01009460A (es) Prediccion de la curacion obstaculizada de lesiones de diabetes por el analisis urinario del nitrato.
Abou-Zamzam Jr et al. Functional outcome after infrainguinal bypass for limb salvage
Nadworny et al. Anti-inflammatory activity of nanocrystalline silver-derived solutions in porcine contact dermatitis
Gottrup et al. Randomized controlled trial on collagen/oxidized regenerated cellulose/silver treatment
Gethin et al. The impact of Manuka honey dressings on the surface pH of chronic wounds
Schorah et al. Gastric juice ascorbic acid: effects of disease and implications for gastric carcinogenesis
Gist et al. Wound care in the geriatric client
Solway et al. A parallel open‐label trial to evaluate microbial cellulose wound dressing in the treatment of diabetic foot ulcers
Gethin The significance of surface pH in chronic wounds
Vlachou et al. The safety of nanocrystalline silver dressings on burns: a study of systemic silver absorption
Gray et al. Moisture vs pressure: making sense out of perineal wounds
DE60113548D1 (de) Cyanomethyl-substituierte thiazolium- und imidazolium-verbindungen und behandlung von erkrankungen im zusammenhang mit proteinalterung
ATE462427T1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
DE60238032D1 (de) Vorhersagen der wundheilung durch harnnitrat-bestimmung
Trignano et al. Evaluation of peripheral microcirculation improvement of foot after tarsal tunnel release in diabetic patients by transcutaneous oximetry
Thomason et al. Silver oxysalts promote cutaneous wound healing independent of infection
Latifa et al. Evaluation of physiological risk factors, oxidant-antioxidant imbalance, proteolytic and genetic variations of matrix metalloproteinase-9 in patients with pressure ulcer
Jude et al. Role of neuropathy and plasma nitric oxide in recurrent neuropathic and neuroischemic diabetic foot ulcers
Burian et al. Wounds in chronic leg oedema
ATE328606T1 (de) Verwendung von thrombin-peptidderivaten zur behandlung von chronischen hautulcera
AU2008327712B2 (en) Diagnostic markers of wound infection
Hanson et al. Understanding wound fluid and the phases of healing
Gon et al. Melanoma in a long‐standing lesion of chromoblastomycosis
Weindorf et al. Non‐interventional study to investigate the efficacy and safety of Tegaderm™ Matrix in the treatment of patients with therapy‐refractory chronic wounds
Bengi et al. Effect of non-surgical periodontal treatment on visfatin and chemerin concentration in the gingival crevicular fluid